UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Uveal Melanoma: Biology and Management

1st Edition 2021, 2021

Volltextzugriff (PDF)

Environmental Oncology: Theory and Impact

1, 2023

Volltextzugriff (PDF)

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma

Clinical lung cancer, 2020-09, Vol.21 (5), p.437-442

2020

Volltextzugriff (PDF)

Cancer and Society: A Multidisciplinary Assessment and Strategies for Action

1st ed. 2019., 2019

Volltextzugriff (PDF)

Update on emerging biomarkers in lung cancer

Journal of thoracic disease, 2019-01, Vol.11 (S1), p.S81-S88

2019

Volltextzugriff (PDF)

Practice Patterns and Outcomes in Elderly Stage I Non–Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis

Clinical lung cancer, 2018-03, Vol.19 (2), p.e269-e276

2018

Volltextzugriff (PDF)

Cell‐free DNA 5‐hydroxymethylcytosine as a marker for common cancer detection

Clinical and translational discovery, 2022-12, Vol.2 (4), p.n/a

2022

Volltextzugriff (PDF)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer

JACC CardioOncology, 2019-12, Vol.1 (2), p.182-192

2019

Volltextzugriff (PDF)

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis

Cells (Basel, Switzerland), 2024-02, Vol.13 (4), p.298

2024

Volltextzugriff (PDF)

5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer

Cells (Basel, Switzerland), 2024-04, Vol.13 (8), p.715

2024

Volltextzugriff (PDF)

What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies

Archives of pathology & laboratory medicine (1976), 2019-09, Vol.143 (9), p.1089-1092

Bernicker, Eric H

2019

Volltextzugriff (PDF)

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)

JACC CardioOncology, 2019-12, Vol.1 (2), p.172-178

2019

Volltextzugriff (PDF)

What the Oncologist Needs From the Pathologist for Immune Therapies

Archives of pathology & laboratory medicine (1976), 2019-12, Vol.143 (12), p.1513-1516

Bernicker, Eric H

2019

Volltextzugriff (PDF)

Impact of Recent Developments in Lung Cancer on the Practice of Pathology

Archives of pathology & laboratory medicine (1976), 2016-04, Vol.140 (4), p.322-325

2016

Volltextzugriff (PDF)

Treatment at Twilight: An Analysis of Therapy Patterns and Outcomes in Adults 80 Years and Older With Advanced or Metastatic NSCLC

JTO clinical and research reports, 2023-10, Vol.4 (10), p.100570-100570, Article 100570

2023

Volltextzugriff (PDF)

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Archives of pathology & laboratory medicine (1976), 2018-03, Vol.142 (3), p.321-346

2018

Volltextzugriff (PDF)

Chemotherapy in non-small cell lung cancer: opportunities for advancement

Ai zheng, 2016-06, Vol.35 (9), p.438-440, Article 56

2016

Volltextzugriff (PDF)

Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis

Advances in radiation oncology, 2021-11, Vol.6 (6), p.100783-100783, Article 100783

2021

Volltextzugriff (PDF)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

JTO clinical and research reports, 2020-06, Vol.1 (2), p.100017-100017, Article 100017

2020

Volltextzugriff (PDF)

DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma

Advances in radiation oncology, 2021-11, Vol.6 (6), p.100719, Article 100719

2021

Volltextzugriff (PDF)

Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma

Graefe's archive for clinical and experimental ophthalmology, 2019-07, Vol.257 (7), p.1541-1545

2019

Volltextzugriff (PDF)

Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non–Small Cell Lung Cancer in a Large Real-World Oncology Database

Archives of pathology & laboratory medicine (1976), 2022-08, Vol.146 (8), p.975-983

2022

Volltextzugriff (PDF)

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Clinical cancer research, 2019-01, Vol.25 (1), p.277-289

2019

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(146)

Publikationsform

Sprache

Englisch
(153)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Uveal Melanoma: Biology and Management

Environmental Oncology: Theory and Impact

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma

Cancer and Society: A Multidisciplinary Assessment and Strategies for Action

Update on emerging biomarkers in lung cancer

Practice Patterns and Outcomes in Elderly Stage I Non–Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis

Cell‐free DNA 5‐hydroxymethylcytosine as a marker for common cancer detection

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis

5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer

What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)

What the Oncologist Needs From the Pathologist for Immune Therapies

Impact of Recent Developments in Lung Cancer on the Practice of Pathology

Treatment at Twilight: An Analysis of Therapy Patterns and Outcomes in Adults 80 Years and Older With Advanced or Metastatic NSCLC

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Chemotherapy in non-small cell lung cancer: opportunities for advancement

Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma

Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma

Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non–Small Cell Lung Cancer in a Large Real-World Oncology Database

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Suchergebnisse filtern